gonadotropin-releasing hormone analogue

(redirected from GnRH analogues)

gonadotropin-releasing hormone analogue

A polypeptide analogue of gonadotropin-releasing hormone–GnRH; some are more potent than GnRH in stimulating gonadotropin release Examples Leuprolide, histrelin, administered in a pulsatile fashion to restore lost GnRH, normalize pituitary-gonadal function, as in congenital GnRH deficiencies–eg, hypogonadotropic hypogonadism with Kallmann syndrome or without anosmia, or in acquired GnRH deficiency secondary to RT of the CNS, pituitary tumors, or panhypopituitarism. See Gonadotropin-releasing hormone.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
-GnRH: GnRH analogues are highly effective in the treatment of severe PMS and are not recommended for use in routine.
Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab 2006;19:1327-34.
[4] GnRH analogues are especially useful for 6-12 months post-surgery, to suppress ectopic endometrial tissue while pleural adhesions form to allow for effective pleurodesis.
Depot leuprolide acetate and nafarelin acetate are GnRH analogues approved by the FDA more than 25 years ago for treatment of pelvic pain caused by endometriosis.
In these trials, ovarian ablation was achieved either reversibly with GnRH analogues or permanently and irreversibly with oophorectomy.
Though the two studies described utilized GnRH analogues, there are many other treatment modalities being investigated including ketoconazole, finasteride, anti-androgens, PDE5 inhibitors, pseudoephedrine, terbutaline, and digoxin (4).
Use of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis.
When an individual is committed to preventing the development of secondary sex characteristics, GnRH analogues ('blockers') can be administered to halt development of puberty.
(6,7) GnRH analogues lead to the desensitisation of pituitary GnRH receptors and block endogenous LH increase.
In the long protocol, downregulation was achieved using GnRH analogues initiated at the start of the proceeding luteal phase, with dosing halved beginning on the day of hyperstimulation and continued until the day of hCG treatment.
Ferriani et al., "Add-back therapy with GnRH analogues for uterine fibroids," The Cochrane database of systematic reviews, vol.
These confounders included age of the women and the total number of oocytes retrieved, quantity of embryos that are transferred and their developmental stage, presence of a minimum one good-quality embryo transferred, BMI of woman, total dosage of FSH used, and the type of GnRH analogues (agonists versus antagonists) for ovarian stimulation.